8-KOther Events

ELI LILLY & Co 8-K Report, Corporate Update (May 29, 2015)

Filed May 29, 2015For Securities:LLY

Summary

Eli Lilly and Company (LLY) announced on May 26, 2015, through an 8-K filing, its entry into an Underwriting Agreement to issue and sell a significant aggregate principal amount of Euro-denominated notes. This issuance includes €600,000,000 in 1.000% Notes due 2022, €750,000,000 in 1.625% Notes due 2026, and €750,000,000 in 2.125% Notes due 2030, totaling €2.1 billion. These notes are being issued under an existing indenture and are registered on a Form S-3. The anticipated closing date for the offering is June 2, 2015, with expected net proceeds of approximately €2,072,719,500 after underwriter discounts. This action indicates Lilly's strategy to access capital markets, potentially to fund operations, investments, or acquisitions, while diversifying its debt structure with long-term, fixed-rate Euro-denominated debt.

Key Highlights

  • 1Eli Lilly issued €2.1 billion in senior notes across three tranches: 1.000% Notes due 2022 (€600M), 1.625% Notes due 2026 (€750M), and 2.125% Notes due 2030 (€750M).
  • 2The offering is expected to close on June 2, 2015.
  • 3The company anticipates net proceeds of approximately €2,072,719,500 after underwriter discounts.
  • 4The issuance was registered on a Form S-3 filing, indicating a standard capital markets transaction.
  • 5The notes are governed by an existing Indenture dated February 1, 1991, with Deutsche Bank Trust Company Americas as successor trustee.
  • 6Lilly has the option to redeem the notes under certain conditions, including tax events or events of default.
  • 7This move demonstrates Lilly's proactive capital management and access to international debt markets.

Frequently Asked Questions

This 8-K filing announces Eli Lilly's agreement to issue and sell a substantial amount of Euro-denominated notes. It provides details on the principal amounts, interest rates, and maturity dates of these notes, signaling a significant capital-raising activity.

Eli Lilly is raising a total of €2.1 billion through the issuance of three series of notes: €600 million of 1.000% Notes due 2022, €750 million of 1.625% Notes due 2026, and €750 million of 2.125% Notes due 2030. The company expects to receive net proceeds of approximately €2,072,719,500.

The notes have varying interest rates and maturity dates: 1.000% with a maturity in 2022, 1.625% with a maturity in 2026, and 2.125% with a maturity in 2030. All notes accrue interest annually and are governed by an existing indenture.

The filing itself does not specify the exact use of the proceeds. However, such significant debt issuances are typically used for general corporate purposes, which can include funding research and development, capital expenditures, potential acquisitions, or refinancing existing debt. For investors, it indicates Lilly's ongoing need for capital to support its business operations and growth strategies.